IPO Year: 2021
Exchange: AMEX
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/22/2023 | $11.00 | Buy | H.C. Wainwright |
| 10/9/2023 | $9.00 | Outperform | Robert W. Baird |
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, titled "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites", has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, IL. This significant milestone reflects Calidi's ongoing commitment to advancing systemic enveloped virotherapy as a transformative approach to target and kill metastatic cancers, which are the leading cause of cancer-related mortali
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities described above public offering were offered pursuant to registration statements on Form S-3 (File No. 333-282456), which were declared effective by the United States Securities and Exchange Commission ("SEC") on O
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share. The closing of the offering is expected to occur on or about January 10, 2025, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering. The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering expenses payable by the Company,
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, presented data at the International Oncolytic Virotherapy Conference (IOVC) and the Society for Immunotherapy of Cancer (SITC) Annual Meeting to support the targeted capabilities of its proprietary RTNova™ systemic enveloped virotherapy technology. This data supports the potential use of RTNova to target every metastatic site in multiple oncology indications including metastatic lung cancer. RTNova is uniquely designed to overcome key challenges in systemic virotherapy, including rapid immun
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities described above public offering were offered pursuant to registration statements on Form S-3 (File No. 333-282456), which were declared effective by the United States Securities and Exchange Commission ("SEC") on Oc
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has priced its public offering of 4,437,869 shares of the Company's common stock at a price of $1.69 per share. The closing of the offering is expected to occur on or about November 15, 2024, subject to the satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering. The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offerings. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as t
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company's systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California.Raised $2 million in a registered direct offering and concurrent private placement. SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antit
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
3 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board Received a new U.S. patent for the company's novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccin
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. This addition increases the board's membership to eight. Dr. Gilbert most recently served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024. Under Dr. Gilbert's leadership, his team of laboratory and clinical investigators conducted groundbreaking research that advanced science in the brain tumor field. He developed robust clinical tria
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company's Board of Directors, effective July 1, 2024. "Dr. Peoples is a highly esteemed figure in the field of cancer immunotherapy, bringing decades of experience in cancer vaccine development and clinical research to our Board," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "Dr. Peoples' pioneering work in cancer immunotherapy and his extensive experience in both clinical and military settings will be invaluable as we advance our portfolio
City of Hope, a leader in cancer research and treatment, was awarded $5.3 million from California Institute for Regenerative Medicine (CIRM) to develop a treatment for metastatic ovarian cancer using Calidi's licensed lead asset, NeuroNova (CLD-101) Announced novel systemic enveloped oncolytic virotherapy platform, RTNova, designed to target diverse tumor types Strengthened team with the appointment of three new members to Scientific and Medical Advisory Board and one member to Board of Directors Issued new U.S. patent covering novel SuperNova (CLD-201) technology platform Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a ne
Antonio Chiocca, M.D., Ph.D., Chair, Department of Neurosurgery at Brigham and Women's Hospital, Co-Director, Institute for the Neurosciences, and Professor of Neurosurgery at Harvard Medical School David T. Curiel, M.D., Ph.D., Professor of Radiation Oncology at the Washington University School of Medicine Burt L. Nabors, M.D., Professor, Vice Chair for Research, and Division Director of Neuro-Oncology at the University of Alabama at Birmingham Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. The
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPré to the company's Board of Directors effective January 1, 2024. The company also announced the resignation of Director Alfonso Zulueta effective November 29, 2023 and the resignation of Director Tom Vecchiolla effective January 1, 2024. "David LaPré brings a wealth of pharmaceutical industry experience, expertise in solving problems unique to this industry, and a solid understanding of the factors that drive shareholder value. His past experiences will help Calidi move forward as a company, advancing our por
Announced first patient dosed by collaborator City of Hope in a Phase 1 clinical trial evaluating CLD-101 in recurrent high-grade glioma patients Presented new preclinical data highlighting CLD-201 (SuperNova) platform technology at SITC 2023 Strengthened leadership with key appointments to management team and Board of Directors Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights. "We are highly encouraged by our clinical progress, highlighted by our partner City of Hope dosing the first patient in June
Antonio F. Santidrian, PharmD, Ph.D., promoted to Chief Scientific Officer and Amish Patel, Ph.D., promoted to Senior Vice President of Technical Operations Alan Stewart appointed to Board of Directors Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced two key promotions from the clinical leadership team and the appointment of a new Board Director. Antonio Santidrian, PharmD, Ph.D., previously Senior Vice President, Global Head of Research and Development, has been promoted to Chief Scientific Officer and Amish Patel, Ph.D., has been promoted to Senior Vice President of Technical Opera
H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00
Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate
ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi: https://www.redchip.com/assets/access/cldi_accessGorilla Technology: https://www.redchip.com/assets/access/grrr_accessIn an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloombe
ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (NASDAQ:GP) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:GreenPower Motor: https://www.redchip.com/assets/access/gp_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Fraser Atkinson, CEO of GreenPower, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to
ORLANDO, FL / ACCESSWIRE / May 24, 2024 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Calidi Biotherapeutics Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Paul Mann, CEO of ASP Isotopes, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate u
ORLANDO, FL / ACCESSWIRE / May 17, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics Inc. (NYSE:CLDI) and Unusual Machines Inc. (NYSE:UMAC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessUnusual Machines: https://www.redchip.com/assets/access/umac_accessIn an exclusive interview, Allan Camaisa, Chief Executive Officer of Calidi Biotherapeutics, appears on the RedChip Small Stocks, Big Money™ show
SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)
S-3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B5 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B5 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
EFFECT - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
S-1 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
424B5 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)
8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)